Movatterモバイル変換

[0]ホーム

Jump to content

Suptavumab

中文

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Suptavumab
Monoclonal antibody
Type	?
Source	Human
Target	respiratory syncytial virus fusion protein
Clinical data
Other names	REGN2222
ATC code	none
Identifiers
CAS Number	1629615-23-1
ChemSpider	none
UNII	A0ZE931055
KEGG	D10991
Chemical and physical data
Formula	C₆₅₀₂H₁₀₀₃₈N₁₇₂₆O₂₀₂₀S₄₂
Molar mass	146054.41 g·mol⁻¹

Suptavumab (INN;^[1] development code (REGN2222) is a humanizedmonoclonal antibody designed for the prevention of medically attendedlower respiratory tract disease due torespiratory syncytial virus.^[2]

This experimental drug candidate was beingdeveloped byRegeneron Pharmaceuticals Inc until it was discontinued after unsuccessful Phase III clinical trials.^[3]^[4]

References

[edit]

^World Health Organization (2016)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115"(PDF).WHO Drug Information.30 (2).
^Sevendal AT, Hurley S, Bartlett AW, Rawlinson W, Walker GJ (September 2024). "Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development".Reviews in Medical Virology.34 (5) e2576.doi:10.1002/rmv.2576.PMID 39209729.
^Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab,American Medical Association.
^"Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.

Monoclonal antibodies forinfectious disease andtoxins

Fungal

Human	Efungumab^†

Viral

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Clesrovimab Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Pemivibart Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sipavibart Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Bacterial

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Toxin

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Suptavumab&oldid=1323906781"

Categories:

Hidden categories:

[8]ページ先頭